A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2016

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 31 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Nov 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 10 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top